Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Home CompaniesRegen BioPharma Inc

Regen BioPharma Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-03T17:02:00Z
VOLUME
136
Market Cap
0.17M

Momentum Score

…

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous dendritic cell treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax, which is treated with siRNA to inhibit NR2F6, with the cells re-infused into the patient; DiffronC, which uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuraCAR, comprising CAR-T cells treated with an shRNA targeting the gene NR2F6. Regen BioPharma was incorporated in 2012 and is based in La Mesa, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.04
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.24M
Revenue Per Share
0.00
Gross Profit TTM
0.24M
Debt / Equity
-0.13
ROE
-
Net Debt
0.79M
ROCE
16.94%
Diluted EPS TTM
-0.02

Insight Announcement

View All

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Income before tax -1.27M -0.87M 1.16M 2.44M 3.41M
Net income -1.27M -0.87M 1.02M 5.49M 1.79M
Selling general administrative 0.47M 0.42M 0.71M 0.30M 0.31M
Gross profit 0.24M 0.16M 0.18M 0.19M 0.11M
Ebit -1.06M -0.94M -0.69M -0.34M -0.20M
Ebitda -1.01M -0.42M -0.94M -0.32M -0.21M
Depreciation and amortization 0.05M 0.52M -0.25M 0.02M 0.00M
Operating income -0.34M -0.42M -0.69M -0.34M -0.21M
Other operating expenses 0.58M 0.65M 0.92M 0.58M 0.32M
Interest expense 0.21M 0.07M 0.06M 0.21M 0.94M
Tax provision 0.00M 0.00M - - -
Interest income - - 0.00M 0.00M 0.00M
Net interest income -0.21M -0.25M -0.31M -0.25M -0.37M
Income tax expense - -0.87M 0.44M -3.05M 1.63M
Total revenue 0.24M 0.24M 0.24M 0.24M 0.11M
Total operating expenses 0.58M 0.58M 0.92M 0.58M 0.32M
Cost of revenue 0.08M 0.08M 0.06M 0.05M 0.03M
Total other income expense net -0.94M -0.45M 2.15M 2.78M 3.62M
Net income from continuing ops -1.27M -0.67M 1.16M 2.44M -6.77M
Net income applicable to common shares - - - 2.23M -6.77M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Total assets 0.27M 0.18M 0.35M 0.56M 0.12M
Other current assets 0.07M 0.06M 0.01M 0.03M 0.00M
Total liab 6.56M 5.37M 5.46M 8.60M 7.46M
Total stockholder equity -6.28M -5.19M -5.10M -8.04M -7.33M
Other current liab 7.54M 3.06M 3.06M 5.57M 2.63M
Common stock 0.00M 0.00M 0.00M 0.50M 0.16M
Capital stock 0.00M 0.00M 0.00M 0.55M 0.48M
Retained earnings -21.69M -20.62M -19.75M -20.91M -16.58M
Other assets - - - - 0.00M
Cash 0.00M 0.00M 0.12M 0.05M 0.73M
Total current liabilities 6.56M 5.37M 5.31M 8.60M 7.46M
Current deferred revenue 1.34M 1.47M 1.61M 1.72M 2.11M
Net debt 0.79M 0.81M 0.64M 1.22M 2.60M
Short term debt 0.79M 0.81M 0.61M 1.27M 2.60M
Short long term debt 1.20M 0.79M 0.61M 1.27M 3.58M
Short long term debt total 0.79M 0.81M 0.76M 1.27M 2.60M
Other stockholder equity 15.63M 14.68M 14.64M 12.32M 9.05M
Total current assets 0.27M 0.16M 0.13M 0.34M 0.10M
Long term investments 0.00M 0.02M 0.22M 0.22M 0.22M
Net tangible assets - - - -8.08M -13.53M
Net receivables 0.20M 0.09M 0.00M 0.25M 0.10M
Long term debt - - 0.15M - -
Accounts payable 0.03M 0.03M 0.03M 0.03M 0.11M
Accumulated other comprehensive income -0.22M 0.74M -0.00M - -
Non current assets total 0.02M 0.02M 0.22M 0.22M 0.02M
Breakdown 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Type yearly yearly yearly yearly yearly
Date 2025-09-30 2024-09-30 2023-09-30 2022-09-30 2021-09-30
Investments - - - 0.03M 0.49M
Change to liabilities - - - -0.19M 1.82M
Total cashflows from investing activities - - - 0.03M 0.49M
Net borrowings 0.34M 0.07M - -0.09M 1.36M
Total cash from financing activities 0.45M 0.57M 0.24M -0.09M -0.03M
Change to operating activities - - - -2.91M 4.59M
Net income -1.27M -0.87M 1.16M 2.44M 3.41M
Change in cash 0.07M -0.12M 0.07M -0.68M -0.01M
Begin period cash flow 0.00M 0.12M 0.05M 0.73M 0.01M
End period cash flow 0.07M 0.00M 0.12M 0.05M 0.73M
Total cash from operating activities -0.38M -0.69M -0.17M -0.61M 0.02M
Issuance of capital stock 0.06M 0.56M - - -
Depreciation 0.05M 0.03M 0.00M 0.07M 0.61M
Change to inventory - - -2.07M - -4.00M
Change to account receivables -0.11M -0.09M 0.25M -0.04M -0.03M
Other cashflows from financing activities 0.05M 0.57M -0.01M -0.14M -0.00M
Change to netincome - - - 0.02M -0.72M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.04M -0.25M -1.93M -3.14M -4.01M
Stock based compensation - 0.01M 0.35M 0.00M 0.00M
Other non cash items 0.80M 0.14M 0.50M 0.02M 0.00M
Free cash flow -0.38M -0.69M -0.17M -0.61M 0.02M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RGBP
Regen BioPharma Inc		 -
-%		 0.00 - - 0.71 251.28 4.54 28.10
NVO
Novo Nordisk A/S		 -0.24
0.61%		 40.20 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -21.28
3.85%		 531.87 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 12.10
1.26%		 973.36 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Regen BioPharma Inc

Regen BioPharma, Inc. focuses on the development of regenerative medical applications in the United States. The company engages in identifying small molecules that inhibit or express NR2F6, leading to immune cell activation for oncology applications and immune cell suppression for autoimmune diseases. It also develops several products: HemaXellarate, a cellular therapeutic product derived from autologous stromal vascular fraction from adipose tissue; dCellVax, an autologous dendritic cell treated with an siRNA inhibitor of indoleamine-2,3-dioxygenase; tCellVax, which is treated with siRNA to inhibit NR2F6, with the cells re-infused into the patient; DiffronC, which uses proprietary siRNA in vivo to inhibit cancer growth and activate T cells; and DuraCAR, comprising CAR-T cells treated with an shRNA targeting the gene NR2F6. Regen BioPharma was incorporated in 2012 and is based in La Mesa, California.

8697 La Mesa Boulevard, La Mesa, CA, United States, 91942

619 722 5505

https://regenbiopharmainc.com

1

Name Title Year Born
Dr. David Raymond Koos Chairman, CEO, Pres, Sec. & Treasurer 1961
Dr. David Raymond Koos DBA, Ph.D. Chairman, CEO, President, Acting CFO, Secretary & Treasurer 1961

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PARA
USD 2.82
+66.86%
AEHR
USD 65.11
+26.50%
CLVT
USD 2.09
+25.90%
BRAI
USD 3.06
+22.40%
ARRY
USD 4.64
+22.24%
SUPN
USD 28.15
-32.85%
STVN
USD 14.10
-28.57%
GTN-A
USD 7.23
-27.63%
LOT
USD 0.29
-27.52%
ADTN
USD 5.03
-19.90%

Equity Sectors*

  • Basic Materials

    -0.39%

  • Communication Services

    +0.40%

  • Consumer Cyclical

    -0.20%

  • Consumer Defensive

    -0.56%

  • Energy

    -0.45%

  • Financial Services

    -0.09%

  • Financials

    +0.11%

  • Healthcare

    +0.40%

  • Industrials

    +0.34%

  • Real Estate

    -0.14%

  • Technology

    +0.88%

  • Utilities

    +0.11%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…